Sign inJoin waitlistJoin the waitlist

Guillermo Bravo

Director, Chronic Myelomonocytic Leukemia (CMML) Program · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2015–2017
University Hospital La Paz
2011–2015
Internal Medicine
2010–2013
Doctor of Medicine
2006–2010

Research

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · 294 citations
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
The Lancet Haematology · 2020 · 280 citations
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
The Lancet Haematology · 2023 · 226 citations

Guillermo Garcia-Manero
158 papers
Hagop Kantarjian
120 papers
Tapan Kadia
120 papers
Elias Jabbour
106 papers
Courtney DiNardo
105 papers
Naval Daver
100 papers
GB
Gautam Borthakur
93 papers
KS
Koji Sasaki
92 papers · 2 as a fellow
Nicholas Short
90 papers · 2 as a fellow
Kelly Chien
76 papers · 5 as a fellow
Rashmi Kanagal-Shamanna
73 papers
Naveen Pemmaraju
66 papers

Clinical trials

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Site PI · Recruiting · Phase 2
Theradex
2026–2028